(Q28299995)

1

0 references

René S. Kahn

6

object named as

René S Kahn

0 references

author name string

Roos van Westrhenen

2

0 references

Marieke J H Begemann

3

0 references

Lot D de Witte

Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia

4

0 references

language of work or name

English

0 references

publication date

January 2014

0 references

published in

Schizophrenia Bulletin

0 references

volume

40

0 references

page(s)

181-91

0 references

issue

1

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Putative neuroprotective agents in neuropsychiatric disorders

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

20 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

20 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Association of schizophrenia and autoimmune diseases: linkage of Danish national registers

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Measuring inconsistency in meta-analyses

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

20 March 2017

Cyclooxygenases 1 and 2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Autoimmune diseases and infections as risk factors for schizophrenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Expression QTL analysis of top loci from GWAS meta-analysis highlights additional schizophrenia candidate genes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

N-Acetylcysteine prevents baker's-yeast-induced inflammation and fever

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Immune and neuroimmune alterations in mood disorders and schizophrenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Promising medications for cocaine dependence treatment.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

The application of PET technique for the development and evaluation of novel antipsychotics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Dietary fatty acids in dementia and predementia syndromes: epidemiological evidence and possible underlying mechanisms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Cytokines and schizophrenia: Microglia hypothesis of schizophrenia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Estrogen in severe mental illness: a potential new treatment approach

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Estrogen - a potential treatment for schizophrenia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Modulation of glutamate receptor functions by glutathione

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Role and regulation of cyclooxygenase-2 during inflammation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Aspirin inhibits vasopressin-induced hypothalamic-pituitary-adrenal activity in normal humans.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Neuroinflammation in schizophrenia-related psychosis: a PET study.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Is cocaine desire reduced by N-acetylcysteine?

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Celecoxib augmentation of continuously ill patients with schizophrenia.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Glucocorticoid interactions with memory function in schizophrenia.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Slow and latent viruses in schizophrenia.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

C-reactive protein is elevated in schizophrenia.

2 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Methotrexate--how does it really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Does minocycline, an antibiotic with inhibitory effects on microglial activation, sharpen a sense of trust in social interaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Protective effects of lithium: a new look at an old drug with potential antioxidative and anti-inflammatory effects in an animal model of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Effect of aminophylline on aspirin penetration into the central nervous system in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Estrogens and men with schizophrenia: is there a case for adjunctive therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: a double-blind, randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Clinical effects of COX-2 inhibitors on cognition in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Effect of a chronic treatment with 17β-estradiol on striatal dopamine neurotransmission and the Akt/GSK3 signaling pathway in the brain of ovariectomized monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Minocycline for patients with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Bioactivation of minocycline to reactive intermediates by myeloperoxidase, horseradish peroxidase, and hepatic microsomes: implications for minocycline-induced lupus and hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Minocycline-induced cutaneous polyarteritis nodosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Minocycline-induced lupus-like disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Why minocycline can cause systemic lupus - a hypothesis and suggestions for therapeutic interventions based on it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Minocycline-induced lupus and autoimmune hepatitis: family autoimmune disorders as possible risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBT139

Lupus syndrome with neutropenia following minocycline therapy - a case report

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3885306

Mechanisms of action of (n-3) fatty acids

27 November 2018

1 reference

12 December 2020

The way in which intervention studies have "personality" and why it is important to meta-analysis

1 reference

12 December 2020

Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial

1 reference

12 December 2020

Hyperthyroidism and lupus-like syndrome in an adolescent treated with minocycline for acne vulgaris

1 reference

12 December 2020

C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia

1 reference

12 December 2020

Schizophrenia genes, epigenetics and psychoneuroimmunology therapeutics: all make sense now?

1 reference

12 December 2020

Identifiers

DOI

10.1093/SCHBUL/SBT139

1 reference

902700

902700

1 reference

1 reference

1 reference